Cheríe S Blair1, Jack Needleman2, Marjan Javanbakht3, W Scott Comulada, Amy Ragsdale, Robert Bolan4, Steven Shoptaw5, Pamina M Gorbach. 1. From the Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at UCLA. 2. Department of Health Policy and Management. 3. Department of Epidemiology, UCLA Fielding School of Public Health. 4. Health and Mental Health Services, Los Angeles LGBT Center. 5. Department of Family Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Abstract
BACKGROUND: Methamphetamine use, sexual risk behaviors, and depression contribute to ongoing human immunodeficiency virus (HIV) and sexually transmitted infection (STI) disparities among men who have sex with men (MSM). The relative contributions of these effects longitudinally are not well understood. METHODS: This analysis used visit-level data from a longitudinal cohort of MSM, half with HIV, in Los Angeles, CA. From August 2014 to March 2020, participants completed follow-up visits every 6 months and underwent testing for rectal gonorrhea/chlamydia (GC/CT) and completed questionnaires including depressive symptoms, number of receptive anal intercourse (RAI) partners, and methamphetamine use. Path analysis with structural equation modeling using concurrent and lagged covariates was used to identify relative contributions of methamphetamine use and depression on number of RAI partners and rectal GC/CT across time. RESULTS: Five hundred fifty-seven MSM with up to 6 visits (3 years) were included for a total of 2437 observations. Methamphetamine use and depressive symptoms were positively associated with number of RAI partners (β = 0.28, P < 0.001; β = 0.33, P = 0.018, respectively), which was positively associated with rectal GC/CT (β = 0.02, P < 0.001). When stratified by HIV status, depressive symptoms were positively associated with RAI partners for HIV-negative MSM (β = 0.50, P = 0.007) but were not associated for MSM living with HIV (β = 0.12, P = 0.57). Methamphetamine use was positively associated with RAI partners in both strata. CONCLUSIONS: Factors and patterns, which contribute to risk behaviors associated with rectal GC/CT, may differ by HIV status. Our findings demonstrate the importance of combined treatment and prevention efforts that link screening and treatment of stimulant use and depression with STI prevention and treatment.
BACKGROUND: Methamphetamine use, sexual risk behaviors, and depression contribute to ongoing human immunodeficiency virus (HIV) and sexually transmitted infection (STI) disparities among men who have sex with men (MSM). The relative contributions of these effects longitudinally are not well understood. METHODS: This analysis used visit-level data from a longitudinal cohort of MSM, half with HIV, in Los Angeles, CA. From August 2014 to March 2020, participants completed follow-up visits every 6 months and underwent testing for rectal gonorrhea/chlamydia (GC/CT) and completed questionnaires including depressive symptoms, number of receptive anal intercourse (RAI) partners, and methamphetamine use. Path analysis with structural equation modeling using concurrent and lagged covariates was used to identify relative contributions of methamphetamine use and depression on number of RAI partners and rectal GC/CT across time. RESULTS: Five hundred fifty-seven MSM with up to 6 visits (3 years) were included for a total of 2437 observations. Methamphetamine use and depressive symptoms were positively associated with number of RAI partners (β = 0.28, P < 0.001; β = 0.33, P = 0.018, respectively), which was positively associated with rectal GC/CT (β = 0.02, P < 0.001). When stratified by HIV status, depressive symptoms were positively associated with RAI partners for HIV-negative MSM (β = 0.50, P = 0.007) but were not associated for MSM living with HIV (β = 0.12, P = 0.57). Methamphetamine use was positively associated with RAI partners in both strata. CONCLUSIONS: Factors and patterns, which contribute to risk behaviors associated with rectal GC/CT, may differ by HIV status. Our findings demonstrate the importance of combined treatment and prevention efforts that link screening and treatment of stimulant use and depression with STI prevention and treatment.
Authors: Peter Freeman; Bendu C Walker; D Robert Harris; Robert Garofalo; Nancy Willard; Jonathan M Ellen Journal: Arch Pediatr Adolesc Med Date: 2011-08
Authors: Christine B Agnew-Brune; Alexandra B Balaji; Brian Mustanski; Michael E Newcomb; Nik Prachand; Sarah L Braunstein; Kathleen A Brady; Brooke E Hoots; Justin S Smith; Gabriela Paz-Bailey; Dita Broz Journal: AIDS Behav Date: 2019-12
Authors: Pamina M Gorbach; Marjan Javanbakht; Chelsea L Shover; Robert K Bolan; Amy Ragsdale; Steven Shoptaw Journal: Sex Transm Dis Date: 2019-02 Impact factor: 2.830
Authors: Thomas C Mills; Jay Paul; Ron Stall; Lance Pollack; Jesse Canchola; Y Jason Chang; Judith T Moskowitz; Joseph A Catania Journal: Am J Psychiatry Date: 2004-02 Impact factor: 18.112